Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

<p>SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/organovo-advances-clinical-timelines-for-fxr314-and-provides-updates-on-nash-phase-2-data/">Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>